Gees Luis,
Talk about misreading what I say. Do you really think they can sell tens of millions of mice a year ? You are basing the assumption of big money on a news released about a mouse model you don't understand.
I have followed this company for years. This other stuff they report is nice and may have potential, but lidakol is what I am waiting for. If the phase 3 study sucks, well there is not much we can do is there. If it's good, then maybe it won't go up too fast and we could get more based on our accumulated knowledge,,,,maybe we would understand the possibilities faster. I will not hype this stock, period. It is risky. But I also think that the risk/return is worth putting a moderate amount on.
By the way, have you noticed how often great phase 2 studies are NOT confirmed on phase 3 studies. When the statistics show the chance of random error is less than 5 or 2.3 or less than 1% (in phase 2 studies), and then the phase 3 studies show NO difference, well then you figure out what is going on with a majority of these biotech companies. I'm not saying that Lidak is doing this, and I have looked over the data they have given, and it looks like they have a very good explaination for what happened. I could detect no contradiction in what they told me and it had the ring of truth. I am long term on this company and do not see the need to hype this stock. You have made misstatements about lidak that try to tell people that there are 3 drugs in phase 3 studies!!!!!!!!!!! Wrong!!!!!!!!! I did not make a big deal about that. Bottom line is that lidak is a decent educated risk. I hope I have not offended you, I welcome your imput as I know you welcome mine. |
